Sotoxen 320 — Sotorasib 320 mg Tablets
Sotoxen 320 mg (Sotorasib) is a breakthrough targeted therapy and a generic equivalent to Lumakras. It is a first-in-class inhibitor of the KRAS G12C protein, a target that was previously considered "undruggable" in oncology.
Manufacturer: Everest Pharmaceuticals (Bangladesh). The drug is designed to treat non-small cell lung cancer by permanently locking the mutated protein in an inactive state.
Key Features:
- ✅ Mechanism of Action: Specifically targets the KRAS G12C mutation, shutting down the signaling pathway that drives cancer cell growth.
- ✅ High Selectivity: Binds only to the mutated protein without affecting the normal (wild-type) KRAS protein, minimizing damage to healthy cells.
- ✅ Clinical Efficacy: Demonstrates rapid and durable tumor shrinkage in patients who have progressed on prior therapies.
Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 21.03.2026
Similar products
What Customers Say
No reviews yet
Your review can be the first!